These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 39325274)

  • 1. Predicting biological activity and design of 5-HT
    de Sousa DS; da Silva AP; Chiari LPA; de Angelo RM; de Sousa AG; Honorio KM; da Silva ABF
    J Mol Model; 2024 Sep; 30(10):350. PubMed ID: 39325274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serotonin 5-HT
    Ferrero H; Solas M; Francis PT; Ramirez MJ
    CNS Drugs; 2017 Jan; 31(1):19-32. PubMed ID: 27914038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serotonin 5-HT6 receptor antagonists for the treatment of cognitive deficiency in Alzheimer's disease.
    Benhamú B; Martín-Fontecha M; Vázquez-Villa H; Pardo L; López-Rodríguez ML
    J Med Chem; 2014 Sep; 57(17):7160-81. PubMed ID: 24850589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug design of new 5-HT
    da Silva AP; Chiari LPA; Guimaraes AR; Honorio KM; da Silva ABF
    J Mol Graph Model; 2021 May; 104():107844. PubMed ID: 33529936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual-acting agents for improving cognition and real-world function in Alzheimer's disease: Focus on 5-HT6 and D3 receptors as hubs.
    Millan MJ; Dekeyne A; Gobert A; Brocco M; Mannoury la Cour C; Ortuno JC; Watson D; Fone KCF
    Neuropharmacology; 2020 Oct; 177():108099. PubMed ID: 32525060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antagonism of the 5-HT
    de Jong IEM; Mørk A
    Neuropharmacology; 2017 Oct; 125():50-63. PubMed ID: 28711518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigational drugs targeting 5-HT6 receptors for the treatment of Alzheimer's disease.
    Wicke K; Haupt A; Bespalov A
    Expert Opin Investig Drugs; 2015; 24(12):1515-28. PubMed ID: 26548316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress in Investigational Agents Targeting Serotonin-6 Receptors for the Treatment of Brain Disorders.
    Nirogi R; Jayarajan P; Shinde A; Mohammed AR; Grandhi VR; Benade V; Goyal VK; Abraham R; Jasti V; Cummings J
    Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The serotonin 5-HT6 receptor: a viable drug target for treating cognitive deficits in Alzheimer's disease.
    Geldenhuys WJ; Van der Schyf CJ
    Expert Rev Neurother; 2009 Jul; 9(7):1073-85. PubMed ID: 19589055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of 5 HT6-receptor antagonists in Alzheimer's disease: an update.
    Khoury R; Grysman N; Gold J; Patel K; Grossberg GT
    Expert Opin Investig Drugs; 2018 Jun; 27(6):523-533. PubMed ID: 29848076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serotonin 5-HT6 receptor antagonists for the treatment of Alzheimer's disease.
    Geldenhuys WJ; Van der Schyf CJ
    Curr Top Med Chem; 2008; 8(12):1035-48. PubMed ID: 18691131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging chemical therapies targeting 5-hydroxytryptamine in the treatment of Alzheimer's disease.
    Calhoun A; Ko J; Grossberg GT
    Expert Opin Emerg Drugs; 2017 Mar; 22(1):101-105. PubMed ID: 28253832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulating 5-HT
    Lalut J; Karila D; Dallemagne P; Rochais C
    Future Med Chem; 2017 May; 9(8):781-795. PubMed ID: 28504917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemical update on the potential for serotonin 5-HT
    Kucwaj-Brysz K; Baltrukevich H; Czarnota K; Handzlik J
    Bioorg Med Chem Lett; 2021 Oct; 49():128275. PubMed ID: 34311086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of novel series of 5-HT6 receptor ligands having indole, a central aromatic core and 1-amino-4 methyl piperazine as a positive ionizable group.
    Hayat F; Cho S; Rhim H; Indu Viswanath AN; Pae AN; Lee JY; Choo DJ; Choo HY
    Bioorg Med Chem; 2013 Sep; 21(17):5573-82. PubMed ID: 23810425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Idalopirdine as a treatment for Alzheimer's disease.
    Galimberti D; Scarpini E
    Expert Opin Investig Drugs; 2015; 24(7):981-7. PubMed ID: 26022777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Phenoxyalkyltriazine Antagonists for 5-HT
    Sudoł S; Cios A; Jastrzębska-Więsek M; Honkisz-Orzechowska E; Mordyl B; Wilczyńska-Zawal N; Satała G; Kucwaj-Brysz K; Partyka A; Latacz G; Olejarz-Maciej A; Wesołowska A; Handzlik J
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel 1H-Pyrrolo[3,2-c]quinoline Based 5-HT6 Receptor Antagonists with Potential Application for the Treatment of Cognitive Disorders Associated with Alzheimer's Disease.
    Grychowska K; Satała G; Kos T; Partyka A; Colacino E; Chaumont-Dubel S; Bantreil X; Wesołowska A; Pawłowski M; Martinez J; Marin P; Subra G; Bojarski AJ; Lamaty F; Popik P; Zajdel P
    ACS Chem Neurosci; 2016 Jul; 7(7):972-83. PubMed ID: 27100049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-HT6 receptor antagonists: prospects for the treatment of cognitive disorders including dementia.
    Johnson CN; Ahmed M; Miller ND
    Curr Opin Drug Discov Devel; 2008 Sep; 11(5):642-54. PubMed ID: 18729016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of 5-HT6 antagonists, Ro-4368554 and SB-258585, in tests used for the detection of cognitive enhancement and antipsychotic-like activity.
    Gravius A; Laszy J; Pietraszek M; Sághy K; Nagel J; Chambon C; Wegener N; Valastro B; Danysz W; Gyertyán I
    Behav Pharmacol; 2011 Apr; 22(2):122-35. PubMed ID: 21301322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.